Novartis
$142.41Change from previous close: −0.11%Absolute change: −$0.16
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 56,674 | 51,722 | 46,660 | 43,461 | 43,974 |
| Cost of revenue | 13,620 | 12,815 | 12,472 | 11,582 | 11,391 |
| Gross profit | 43,054 | 38,907 | 34,188 | 31,879 | 32,583 |
| Selling, general and administrative | 13,238 | 12,564 | 12,517 | 12,193 | 12,756 |
| Research and development | 10,687 | 9,511 | 11,371 | 9,172 | 8,259 |
| Operating income | 19,005 | 16,320 | 10,234 | 9,213 | 10,963 |
| EBIT | 19,005 | 16,320 | 10,234 | 9,213 | 10,963 |
| EBITDA | 23,473 | 20,662 | 18,158 | 13,940 | 15,633 |
| Interest expense | 1,144 | 1,006 | 855 | 800 | 787 |
| Pre-tax income | 16,352 | 13,640 | 9,123 | 7,177 | 24,530 |
| Income tax | 2,385 | 1,701 | 551 | 1,128 | 1,625 |
| Net income | 13,984 | 11,941 | 14,850 | 6,955 | 24,021 |
| Net income to common shareholders | 13,984 | 11,941 | 14,850 | 6,955 | 24,021 |
| Basic EPS | 7.21 | 5.92 | 7.15 | 3.19 | 10.71 |
| Diluted EPS | 7.15 | 5.87 | 7.10 | 3.17 | 10.63 |
| Average shares (basic) | 1,939 | 2,018 | 2,077 | 2,181 | 2,243 |
| Average shares (diluted) | 1,955 | 2,035 | 2,092 | 2,197 | 2,260 |
| Dividend per share | 4.67 | 3.86 | 3.92 | 3.46 | 3.40 |